Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe some news after the offering closes, maybe earlier than 5 april ?
Call already at 4pm instead 6pm as released before
Any reason why ?
Stock is halted news coming
Who are those experts ?
Based on discussions over the past several months with a number of experts in the field regarding our AIM2CERV trial, we have become increasingly optimistic about the prospects of this study. We believe that continuing to invest in this study, along with certain other product candidates, provides us with a diversified portfolio across drug constructs, cancer types and stages of development,” said Kenneth A. Berlin, President and Chief Executive Officer of Advaxis. “We believe this approach affords the best opportunity to demonstrate the therapeutic potential of drug candidates generated from our unique and proprietary Lm platform.” He concluded, “The redesign of AIM2CERV with an earlier interim analysis would allow us to alter course or, if necessary, stop the study, depending on the results.
Maybe also some PR today ?
A (very) new Corporate presentation
https://www.advaxis.com/wp-content/uploads/2019/01/Corporate-Presentation-January-2019.pdf
Asked per mail, no answer yet maybe we should all ask ?
No premarket ?
Hugh. No trading yesterday
SOL Global Investments Corp. today makes a statement on the September 27, 2018 sale of it's Latin America operations, LATAM Holdings Inc., to Aphria Inc.
TORONTO, Dec. 5, 2018 /CNW/ - SOL Global Investments Corp. ("SOL Global" or the "Company") (CSE: SOL) (OTCQB: SOLCF) (Frankfurt:9SB) today makes a statement on the September 27, 2018 sale of its Latin American operations, LATAM Holdings Inc., to Aphria Inc.
Brady Cobb, SOL Global's Chief Executive Officer, releases the following statement: "SOL Global completed the sale of its Latin American assets to Aphria Inc. on September 27, 2018. These assets included valuable licenses and strategic partnerships with governments and regulators in each of the Colombian, Argentinian, and Jamaican markets. The sale also included a right of first offer and refusal in respect of an asset in Brazil. These emerging market licenses represent some of the most significant growth opportunities in the global cannabis and CBD marketplaces.
SOL Global reiterates that it is satisfied with the outcome of the transaction. The transaction – as with all transactions of this size - was thoroughly reviewed by both parties, each of which employed qualified and reputable financial analysts and prominent law firms to review the terms of the deal and received a formal valuation and majority of the minority shareholder approval as required by applicable Canadian securities laws. The transaction also received approval by the TSX and the CSE.
Sol Global - and numerous other prominent cannabis companies - have recognized that the cannabis market in Latin America has not yet realized its massive potential. Favorable climate conditions in many Latin American countries, along with continued liberalization of government regulation and the comparatively lower cost of production and cultivation, will make Latin American countries a major participant in the emerging global cannabis economy over the next decade and beyond.
Quintessential Capital Management and Hindenburg Research are financially invested in destroying the stock prices of SOL Global and other cannabis companies by publicizing false and/or purposely misleading information to apply negative pressure to stock prices. Our company will not engage in a back-and-forth with these bad-faith actors at this time. Further, we will be empaneling a special committee of our Board as well as engaging independent counsel to review the false allegations levied against SOL Global by these bad actors and to pursue all available legal relief against parties that have manipulated SOL Global's stock price via false and/or misleading information.
We welcome our current investors and potential new investors to look closely at our capital investments and financial statements and performance before they invest with us, and would expect nothing less."
About SOL Global Investments Corp.
Just as Anavex already does ?
http://c.newsnow.co.uk/A/965416306?-17462:2765
Must there be some PR before opening if there us some relevant news ?
Pencil is loaded wireless just said at the live event
When are abstracts available?
All embargoed abstracts will be made available on October 27th at 5pm Paris Time at www.ctad-alzheimer.com. Our embargo policies are strictly enforced. All research is embargoed until the date/time that it is shared at a CTAD presentation, symposia or poster session. After the abstract presentation, you may publish/write on the abstract content.
Can I discuss CTAD abstract content before the embargo lifts?
Presentation or discussion of embargoed content at satellite meetings or press conferences before the CTAD embargo lifts is prohibited.
Always negative
... at this time... says enough
He also said there will be some data published on a scientific meeting at the end on this month
Slides of presentation available now
Sept 14 (Reuters) - Advaxis Inc :
* CVI INVESTMENTS INC REPORTS 6.0 PERCENT PASSIVE STAKE IN
ADVAXIS
INC AS OF SEPTEMBER 7 - SEC FILING
Source text for Eikon: [ID: (http://bit.ly/2NbAdqe)
Further company coverage:
On Alzheimers news 24 7
http://c.newsnow.co.uk/A/952152651?-17462:2765
Precision medicine offers a glimmer of hope for Alzheimer's disease
Seen this already ? At least
http://c.newsnow.co.uk/A/948127060?-17462:2765